
Although Novavax, Inc’s (NASDAQ:NVAX) shares have tanked 59% year to date, there is still room for a further decline, according to BofA Securities.
The Novavax Analyst: Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.